Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

Eliasson, B, Gudbjörnsdottir, S, Cederholm, J, Liang, Y, Vercruysse, F, Smith, U · 2007 · International Journal of Obesity

Abstract

Objective To examine the metabolic effects and body composition changes after topiramate treatment of obese type 2 diabetic patients (DM2) for 11 months. Design and subjects Thirty-eight DM2 on diet or sulfonylurea treatment participated in this randomized double-blind placebo-controlled trial. Thirteen placebo-treated and nine topiramate-treated patients completed the trial. Patients were randomized to treatment with topiramate 96 mg b.i.d. or placebo (6-week run-in phase, 2-months titration phase, 9-months maintenance phase). Measurements Insulin sensitivity was measured with euglycaemic hyperinsulinemic clamps. Weight, HbA1c, fasting glucose, blood lipids and safety variables were measured at regular intervals. Body composition was determined with computerized tomography. Meal tests were performed to evaluate postprandial glucose and insulin levels. Three-day diet recalls were carried out to evaluate energy ingestion. Results The mean age was 58.6+/-7.1 years, body weight 98.1+/-16.1 kg, BMI 33.0+/-4.5 kg/m(2), and glycosylated hemoglobin (HbA1c) 7.3+/-0.9%. In topiramate-treated patients, there were significant reductions in HbA1c (1.1+/-0.9%), fasting plasma glucose, body weight (-6.6+/-3.3%), as well as body fat, lean body mass, postprandial glucose and free fatty acid levels but there were no significant changes in insulin sensitivity. The daily average energy intake decreased more in the topiramate group than in the placebo group. Paresthesia and central nervous syste…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0803548

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 59

Metadata

Authors
Eliasson, B., Gudbjörnsdottir, S., Cederholm, J., Liang, Y., Vercruysse, F., & Smith, U.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Uppsala University Hospital (SE)
  • Janssen Research & Development (United States) (US)
Corresponding author
Eliasson, B
Venue
International Journal of Obesity
Published
2007-02-13
Volume
31
Issue
7
Pages
1140-1147
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W2052347592
Cited by
57
References
22
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 6 · 2013: 6 · 2012: 3
FWCI
3.90
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
topiramate, type 2 diabetes, obesity, weight loss, body composition, insulin sensitivity, glycemic control, HbA1c, fat mass, energy intake, postprandial blood glucose, insulin secretion, adverse effects
MeSH terms
Topiramate, Adult, Aged, Body Composition, Cells, Cultured, Diabetes Mellitus, Type 2, Dietary Fats, Double-Blind Method, Drug Therapy, Combination, Female, Fructose, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Obesity, Placebos, Sulfonylurea Compounds, Weight Loss, Cytokines, Adipocytes, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1038/sj.ijo.0803548
The paper
Eliasson, B., Gudbjörnsdottir, S., Cederholm, J., Liang, Y., Vercruysse, F., & Smith, U. (2007). Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. International Journal of Obesity. https://doi.org/10.1038/sj.ijo.0803548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.